Tuesday, October 4, 2022


Biotechnology News Magazine

CN Bio Opens New Lab Facilities

To extend Organ-on-a-chip contract research services capabilities

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the opening of new laboratory facilities at Cambridge Science Park, dedicated to its contract research services.

The Company’s laboratory space has doubled in response to the increasing market demand for OOC services as the technology gains traction within drug discovery and development programs.

CN Bio’s contract research services harness the Company’s next-generation MPS technology, a decade of expertise, and proven track record across a growing portfolio of applications including drug metabolism, safety toxicology, oncology, and Non-Alcoholic Steatohepatitis (NASH). Generating actionable data for its customers within weeks, the team collaborates with researchers to create an experimental design that delivers unique human-translatable insights, whilst saving significant time and cost versus animal studies.

The rising demand for services demonstrates the acceptance of OOC data by pharma and biotech companies in their therapeutic programs. This is being fuelled by repeat business, growing interest from regulatory agencies, the technology’s ability to predict clinical outcomes, and its potential to replace animal models – especially for the testing of new drug modalities with human-specific modes of action. As the body of evidence demonstrating OOC’s superior performance versus traditional approaches increases, the Company’s expansion ensures it is ready to meet the needs of this growing market.

Dr Gareth Guenigault, the Lead Scientist of CN Bio’s Contract Research Services, said: “This expansion is an exciting next step in the progression of our contract research services offering. As we see increasing awareness within the drug discovery, development, and regulatory fields that animal models don’t always get it right, nor are ethically desirable, we are poised to offer solutions that fit researchers’ individual needs. By utilizing the power of OOC technology to provide early stage, clinically translatable data across a range of applications, we hope to give customers greater confidence in the success of their projects, in a fraction of the time and cost.”

Read other news of interest here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine